<DOC>
	<DOC>NCT02321839</DOC>
	<brief_summary>To evaluate the visual outcome, number of injections and visits, and the effect of mental status of a treat and extend regimen in managing neovascular age-related macular degeneration with intravitreal ranibizumab.</brief_summary>
	<brief_title>Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular AMD.</brief_title>
	<detailed_description>Treat and Extend Regimen (TER) may contribute to the improvement to a patients' mentality, since the treatment intervals are extended if there were no signs of recurrence. Therefore, we have planned to examine the psychological impact of TER using Hospital Anxiety and Depression Scale (HADS), in addition to the improvement of visual acuity and central retinal thickness.</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Signed informed consent form Male or female of aged 50 years or older Typical AMD and PCV patients BCVA of 24 letters or over Total lesion area of ＞12 DA or ＞30.5 mm2 The existence of subretinal hemorrhage area constituting ≥50% of total lesion area The existence of scar or fibrosis area constituting ≥50% of total lesion area The existence of RPE tear Prior treatment for wet AMD History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD The pregnant or lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>neovascular age-related macular degeneration</keyword>
	<keyword>Ranibizumab</keyword>
	<keyword>Treat and extend</keyword>
</DOC>